Printer Friendly

Learning genetic risk for AD: not so distressing?

AT AAIC 2013

BOSTON--Cognitively normal adults who learn that they are at high risk for developing Alzheimer's disease do not, as some clinicians fear, spiral downward into depression, anxiety, or distress, investigators reported at the Alzheimer's Association International Conference 2013.

An analysis of data from three randomized trials testing the effects of genetic testing disclosure found that that cognitively normal adults who learned that they were homozygous for the high-risk apolipoprotein E epsilon-4 allele (APOE epsilon-4) had a spike in test-specific distress score until about 6 months after learning the results but returned to levels similar to those of heterozygous carriers, reported Dr. Jason Karlawish, professor of medicine at the University of Pennsylvania, Philadelphia, and his colleagues.

However, both homozygous and heterozygous APOE epsilon-4 carriers had more test-specific distress than did carriers of other APOE alleles, noted coauthor Leo B. Waterston of Harvard Medical School, Boston.

"While there is no question that learning that you're at higher risk causes some test-specific distress, this further validates that there is no long-term, sustained psychological distress," Dr. Karlawish said in an interview. People who learned that they were at high risk for developing Alzheimer's disease (AD) were significantly more like to adopt putative AD risk-reducing behaviors, such as dietary changes, exercise, and medication or vitamin supplementation.

The authors looked at participants in three Risk Evaluation and Education for Alzheimer's Disease (REVEAL) trial cohorts. The REVEAL study is a series of multicenter trials looking at the effects of APOE genotyping. They pooled data from three randomized REVEAL trials on a total of 648 patients, identifying 399 (62%) participants who were negative for the epsilon-4 allele, 221 (34%) who were heterozygous carriers of the epsilon-4 allele, and 28 (4%) who were epsilon-4 homozygotes.

They found that epsilon-4 homozygotes and heterozygotes had significantly higher mean test-specific distress levels, compared with noncarriers (P less than .0001), but there were no significant differences between the two epsilon-4-positive groups.

Asked at 1-year follow-up how they perceived their risk for AD, 64% of heterozygous carriers and 72% of homozygous carriers rated their risk as high or very high, a difference that was not significant. In contrast, about half of all noncarriers rated their risk as average and about 15% rated it as high, but none rated their risk as very high.

No significant differences in mean depression scores were found on the Center for Epidemiologic Studies Depression Scale.

The research was supported by grants from the National Institutes of Health. Dr. Karlawish and Mr. Waterston reported having no financial disclosures.

cpnnews@frontlinemedcom.com
COPYRIGHT 2013 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:NEUROLOGY
Author:Osterweil, Neil
Publication:Clinical Psychiatry News
Date:Sep 1, 2013
Words:423
Previous Article:Cognition and postmenopause: two studies, two conclusions.
Next Article:Exercise in young adulthood may benefit brain later.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters